To a large extent, NASA resisted this change during the remainder of the Trump administration, keeping its core group of major contractors, such as Boeing and Lockheed Martin, in place. It had help from key US Senators, including Richard Shelby, the now-retired Republican from Alabama. But this time, the push for change is likely to be more concerted, especially with key elements of NASA’s architecture, including the Space Launch System rocket, being bypassed by privately developed rockets such as SpaceX’s Starship vehicle and Blue Origin’s New Glenn rocket.
Not one, but both
In all likelihood, NASA will adopt a new “Artemis” plan that involves initiatives to both the Moon and Mars. When Musk said “we’re going straight to Mars,” he may have meant that this will be the thrust of SpaceX, with support from NASA. That does not preclude a separate initiative, possibly led by Blue Origin with help from NASA, to develop lunar return plans.
Isaacman, who is keeping a fairly low profile ahead of his nomination, has not weighed in on Musk’s comments. However, when his nomination was announced one month ago, he did make a germane comment on X.
“I was born after the Moon landings; my children were born after the final space shuttle launch,” he wrote. “With the support of President Trump, I can promise you this: We will never again lose our ability to journey to the stars and never settle for second place. We will inspire children, yours and mine, to look up and dream of what is possible. Americans will walk on the Moon and Mars and in doing so, we will make life better here on Earth.”
In short, NASA is likely to adopt a two-lane strategy of reaching for both the Moon and Mars. Whether the space agency is successful with either one will be a major question asked of the new administration.
Work toward brain-computer interfaces has never been more charged. Though neuroscientists have toiled for decades to tap directly into human thoughts, recent advances have the field buzzing with anticipation—and the involvement of one polarizing billionaire has drawn a new level of attention.
With competition amping up in this space, Ars spoke with Ben Rapoport, who is a neurosurgeon, electrical engineer, and co-founder of the brain-computer interface (BCI) company Precision Neuroscience. Precision is at the forefront of the field, having placed its BCI on the brains of 14 human patients so far, with two more scheduled this month. Rapoport says he hopes to at least double that number of human participants by the end of this year. In fact, the 3-year-old company expects to have its first BCI on the market next year.
In addition to the swift progress, Precision is notable for its divergence from its competitor’s strategies, namely Neuralink, the most high-profile BCI company and headed by Elon Musk. In 2016, Rapoport co-founded Neuralink alongside Musk and other scientists. But he didn’t stay long and went on to co-found Precision in 2021. In previous interviews, Rapoport suggested his split from Neuralink related to the issues of safety and invasiveness of the BCI design. While Neuralink’s device is going deeper into the brain—trying to eavesdrop on neuron signals with electrodes at close range to decode thoughts and intended motions and speech—Precision is staying at the surface, where there is little to no risk of damaging brain tissue.
Shallow signals
“It used to be thought that you needed to put needle-like electrodes into the brain surface in order to listen to signals of adequate quality,” Rapoport told Ars. Early BCIs developed decades ago used electrode arrays with tiny needles that sink up to 1.5 millimeters into brain tissue. Competitors such as Blackrock Neurotech and Paradromics are still developing such designs. (Another competitor, Synchron, is developing a stent-like device threaded into a major blood vessel in the brain.) Meanwhile, Neuralink is going deeper, using a robot to surgically implant electrodes into brain tissue, reportedly between 3 mm and 8 mm deep.
However, Rapoport eschews this approach. Anytime something essentially cuts into the brain, there’s damage, he notes. Scar tissue and fibrous tissue can form—which is bad for the patient and the BCI’s functioning. “So, there’s not infinite scalability [to such designs],” Rapoport notes, “because when you try to scale that up to making lots of little penetrations into the brain, at some point you can run into a limitation to how many times you can penetrate the brain without causing irreversible and undetectable damage.”
Further, he says, penetrating the brain is just unnecessary. Rapoport says there is no fundamental data that suggests that penetration is necessary for BCIs advances. Rather, the idea was based on the state of knowledge and technology from decades ago. “It was just that it was an accident that that’s how the field got started,” he said. But, since the 1970s, when centimeter-scale electrodes were first being used to capture brain activity, the technology has advanced from the macroscopic to microscopic range, creating more powerful devices.
“All of conscious thought—movement, sensation, intention, vision, etc.—all of that is coordinated at the level of the neocortex, which is the outermost two millimeters of the brain,” Rapoport said. “So, everything, all of the signals of interest—the cognitive processing signals that are interesting to the brain-computer interface world—that’s all happening within millimeters of the brain surface … we’re talking about very small spatial scales.” With the more potent technology of today, Precision thinks it can collect the data it needs without physically traversing those tiny distances.
Elon Musk’s brain-machine interface (BMI) company Neuralink has been fairly quiet since it last showed off a live trial of the company’s implant in a macaque early last year. Although originally scheduled for October 31st, Musk says a “show & tell” update is coming on November 30th.
The event is said to take place on November 30th at 6: 00 PM PT (local time here). The company’s Twitter profile left a possible hint at this year’s update in an announcement, and it appears to be focused on text input.
The company says in its application FAQ it hasn’t yet begun clinical trials, although BMI text input may be difficult to prove in non-human subjects, so we’ll just have to wait and see.
Like many of Musk’s startups, Neuralink has some fairly lofty goals. The company says in the near-term it wants to help those with paralysis and neurological conditions and disorders and “reduce AI risk to humanity in the long term.”
Here’s a quick recap of events to bring you up to speed for Wednesday’s show and tell:
